import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "peptide-research-documentation-lab-notebook-best-practices",
  title: "Peptide Research Documentation: Lab Notebook and Data Management Best Practices",
  description:
    "A practical guide to research documentation standards for peptide studies — covering electronic lab notebooks, COA filing, compound tracking, reproducibility requirements, and data integrity practices for preclinical research.",
  category: "Research Protocols",
  readMinutes: 9,
  publishedAt: "2026-06-12",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Research reproducibility in peptide science is a known challenge. A 2022 analysis of preclinical pharmacology studies estimated that fewer than 50% of published experiments could be fully reproduced, with incomplete documentation cited as a leading contributing factor. For peptide research specifically — where compound purity, reconstitution protocols, storage history, and administration timing all introduce meaningful variability — rigorous documentation is not procedural overhead. It is the scientific foundation that allows results to mean something.",
    },
    {
      type: "paragraph",
      text: "This guide establishes practical documentation standards for individual researchers and small-to-mid-size labs running peptide studies, from compound receipt through data analysis and publication.",
    },
    {
      type: "heading",
      text: "The Compound Record: What to Document at Receipt",
    },
    {
      type: "paragraph",
      text: "Every peptide compound that enters a research environment should generate an immediate record at receipt. This record becomes the chain-of-custody document that links experimental outcomes to specific material batches — essential when troubleshooting anomalous results or responding to replication requests.",
    },
    {
      type: "subheading",
      text: "Minimum Receipt Documentation",
    },
    {
      type: "list",
      items: [
        "Supplier name, order number, and order date",
        "Compound name (IUPAC and common name), CAS number, and molecular weight",
        "Lot/batch number from COA",
        "Stated purity (HPLC percentage) and analytical method",
        "COA scan or file attached to compound record — not just 'on file'",
        "Vial quantity, mass per vial, and physical form (lyophilized vs. solution)",
        "Date received, condition on receipt (intact seal, desiccant present, no discoloration)",
        "Initial storage location and temperature",
        "Researcher initials",
      ],
    },
    {
      type: "paragraph",
      text: "Thermal indicator strips on packaging should be checked and their result documented. A 'passed' or 'excursion detected' note in the receipt record can prevent weeks of troubleshooting if results later appear anomalous.",
    },
    {
      type: "heading",
      text: "COA Filing and Verification",
    },
    {
      type: "paragraph",
      text: "A Certificate of Analysis is only as useful as it is accessible and verifiable. The common practice of filing COAs in a shared folder with filenames like 'COA.pdf' fails on both counts. A functioning COA system requires:",
    },
    {
      type: "subheading",
      text: "File Naming Convention",
    },
    {
      type: "paragraph",
      text: "Adopt a standardized naming convention that encodes compound, supplier, batch, and date. Example: BPC157_Nexphoria_Lot2024-B7_received20260612.pdf. This allows instant identification without opening the file and enables batch-specific lookup when reviewing experimental records.",
    },
    {
      type: "subheading",
      text: "COA Verification Checklist",
    },
    {
      type: "list",
      items: [
        "Purity stated as percentage by HPLC area — not estimated or 'calculated'",
        "Molecular identity confirmed by mass spectrometry (MW match within 0.1 Da)",
        "Endotoxin (LAL) test result — threshold typically <1.0 EU/mg for parenteral research use",
        "Sterility test result if applicable",
        "Third-party lab name visible on COA — internal testing alone is insufficient for publication-grade documentation",
        "Batch number on COA matches batch number on vial label",
        "COA date is recent (within 12 months of receipt for standard compounds)",
      ],
    },
    {
      type: "callout",
      text: "If a supplier cannot provide batch-specific COAs with third-party testing documentation on demand, that is a disqualifying quality control finding. Never proceed with research using a compound whose purity and identity cannot be verified to this standard.",
    },
    {
      type: "heading",
      text: "Reconstitution Records",
    },
    {
      type: "paragraph",
      text: "Reconstitution is a critical step that transforms lyophilized peptide powder into a research-ready solution — and it is also a common source of undocumented variability. A reconstitution record should be created for every working solution preparation, separate from the compound receipt record.",
    },
    {
      type: "subheading",
      text: "Reconstitution Record Template",
    },
    {
      type: "table",
      headers: ["Field", "Example"],
      rows: [
        ["Date", "2026-06-12"],
        ["Researcher", "Initials/name"],
        ["Compound", "BPC-157, Lot 2024-B7"],
        ["Vial mass used", "5.0 mg"],
        ["Solvent", "Bacteriostatic water (0.9% benzyl alcohol)"],
        ["Volume added", "2.5 mL → 2 mg/mL stock"],
        ["Final concentration", "2,000 µg/mL"],
        ["pH verified", "Yes — pH 7.0 by strip"],
        ["Solution appearance", "Clear, colorless, no particulates"],
        ["Aliquot volumes", "10 × 250 µL aliquots"],
        ["Storage", "−20°C, amber tubes, labeled"],
        ["Stability window", "4 weeks at −20°C per literature"],
        ["Discard date", "2026-07-10"],
      ],
    },
    {
      type: "paragraph",
      text: "Aliquot-based storage — preparing small single-use volumes rather than repeatedly drawing from a master stock — dramatically reduces freeze-thaw degradation and makes concentration tracking more precise. For expensive or limited compounds, aliquot size should be matched to single administration volume to prevent waste.",
    },
    {
      type: "heading",
      text: "Study Log Structure",
    },
    {
      type: "paragraph",
      text: "The study log is the chronological record of experimental execution. Electronic lab notebooks (ELNs) have largely replaced paper formats in modern labs, but the data fields required are the same regardless of format.",
    },
    {
      type: "subheading",
      text: "Daily Study Log Minimum Fields",
    },
    {
      type: "list",
      items: [
        "Study ID and protocol version number",
        "Date and time of all administrations",
        "Compound name, lot number, and aliquot ID administered",
        "Calculated and verified dose (µg/kg), administration route, and injection site",
        "Subject IDs, body weights (for dose calculation verification)",
        "Behavioral observations at administration and time points post-administration",
        "Any adverse events, deviations from protocol, or technical failures",
        "Researcher initials for each entry",
        "Countersignature if required by institutional protocol",
      ],
    },
    {
      type: "paragraph",
      text: "Timestamps matter. In pharmacokinetic and time-course studies, administration time recorded to the minute is often required for meaningful data analysis. The habit of recording 'morning dosing' without clock times is a documentation failure that cannot be retroactively corrected.",
    },
    {
      type: "heading",
      text: "Electronic Lab Notebooks: Selection and Use",
    },
    {
      type: "paragraph",
      text: "ELN adoption in academic and small commercial labs has accelerated significantly in the 2020s. Key platforms used in preclinical research contexts include Benchling (dominant in biotech), LabArchives (popular in academic), eLabFTW (open-source, self-hosted), and Notion-based templates for lightweight use cases. Selection criteria should include:",
    },
    {
      type: "list",
      items: [
        "21 CFR Part 11 compliance if regulatory submission is a possibility",
        "Audit trail — all edits are logged with timestamp and user ID",
        "Attachment support — COAs, images, raw data files",
        "Version history for protocols — know exactly which protocol version was active for each run",
        "Export capability — data portability prevents vendor lock-in and supports long-term archival",
      ],
    },
    {
      type: "paragraph",
      text: "Regardless of platform, the discipline of same-day entry is more important than the choice of software. ELN entries made from memory two days after an experiment are not documentation — they are reconstruction, and reconstruction introduces error.",
    },
    {
      type: "heading",
      text: "Data Integrity and Reproducibility Standards",
    },
    {
      type: "paragraph",
      text: "Research documentation serves two audiences: yourself six months from now, and a replication lab with none of your context. Writing for the latter standard automatically satisfies the former.",
    },
    {
      type: "subheading",
      text: "ARRIVE 2.0 Guidelines",
    },
    {
      type: "paragraph",
      text: "The ARRIVE (Animal Research: Reporting of In Vivo Experiments) 2.0 guidelines, published in 2020, provide the consensus standard for what must be reported in publications of animal research. For documentation purposes, writing study logs with ARRIVE 2.0 fields in mind ensures that all publication-required information is captured at the time of experiment execution — not reconstructed during manuscript preparation. Key ARRIVE 2.0 fields particularly relevant to peptide studies include: compound identity and source, purity and stability data, reconstitution details, administration route justification, and blinding procedures.",
    },
    {
      type: "subheading",
      text: "Blinding and Randomization Records",
    },
    {
      type: "paragraph",
      text: "Allocation concealment and outcome assessment blinding are among the most impactful quality factors in preclinical research. Documentation of randomization sequences, group assignments, and blinding procedures should be maintained in a separate, locked record that is unsealed only after data collection is complete. The existence of a blinding record — and its contents — should be documented even if full blinding was not implemented (with explicit rationale for any deviation).",
    },
    {
      type: "heading",
      text: "Archival and Retention",
    },
    {
      type: "paragraph",
      text: "Research documentation has a longer useful life than most researchers anticipate. NIH-funded research typically requires data retention for a minimum of 3 years post-publication; GLP (Good Laboratory Practice) regulated research requires 10+ years; some regulatory-track data must be retained indefinitely. Even in non-regulated academic contexts, retaining complete records for 7–10 years is defensible best practice given the increasing prevalence of data availability requests and post-publication scrutiny.",
    },
    {
      type: "list",
      items: [
        "Raw data files should be backed up in at least two separate locations (institutional server + external backup)",
        "COAs and compound records should be retained for the lifetime of any publication using that compound",
        "Animal records must meet institutional IACUC retention requirements",
        "ELN exports should be generated annually and archived in non-proprietary formats (PDF, CSV)",
      ],
    },
    {
      type: "paragraph",
      text: "Documentation quality is ultimately an expression of research quality. The rigor applied to recording what was done, with what compound, at what purity, by which procedure, is the same rigor that makes experimental results trustworthy — and replicable.",
    },
    {
      type: "disclaimer",
      text: "All protocols and compound use described in this guide refer to qualified preclinical research conducted under appropriate institutional oversight. Nothing in this guide constitutes advice for human compound use, clinical application, or regulatory submission without appropriate expert consultation.",
    },
  ],
};
